Introduction and Objective: Studies report that COVID-19 illness increases diabetes risk, but the clinical course of incident diabetes following COVID-19 illness is unknown. We compared the course of new onset diabetes in American Indian and Alaska Native people with and without evidence of prior COVID-19 illness.Methods: We used de-identified patient data from the Indian Health Service’s National Patient Information Reporting System to identify individuals with new onset diabetes from 3/1/2020-12/31/2021. We created cohorts with and without documented COVID-19 infection (diagnosis codes and labs) preceding diabetes diagnosis. We excluded individuals with prevalent diabetes (diagnosis codes, labs, and medication data) from three years prior to cohort entry. We compared baseline characteristics and glycemic control (A1c and severe glycemic events) and diabetes medication use over one year of follow up between cohorts.Results: We identified new diabetes diagnoses in 3,164 people with and 24,218 people without antecedent COVID-19 infection. Baseline characteristics and A1c values at diagnosis and one year were similar across cohorts. A greater percentage of the COVID-19 cohort received diabetes medication.Conclusion: Individuals diagnosed with diabetes following COVID-19 illness had A1c levels similar to the no-COVID-19 cohort but were more likely to receive diabetes medication.
J. Keck: None. S. Bressler: None. M.E. Lacy: None.
National Institutes of Health (R34DK132548-01S1)
Source link
Leave a Reply